Corium International Inc. (NASDAQ:CORI) has been assigned a $16.00 target price by equities researchers at Leerink Swann in a report issued on Tuesday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Leerink Swann’s price target suggests a potential upside of 240.43% from the stock’s previous close.

A number of other equities research analysts have also commented on CORI. FBR & Co set a $18.00 price target on Corium International and gave the company a “buy” rating in a research report on Friday, August 5th. Zacks Investment Research lowered Corium International from a “buy” rating to a “hold” rating in a research report on Wednesday, August 10th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $15.00 price target on shares of Corium International in a research report on Monday, September 26th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $12.25.

Analyst Recommendations for Corium International (NASDAQ:CORI)

Corium International (NASDAQ:CORI) opened at 4.70 on Tuesday. Corium International has a 12-month low of $3.14 and a 12-month high of $9.93. The company’s 50 day moving average price is $5.04 and its 200-day moving average price is $4.71. The company’s market capitalization is $104.37 million.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Paloma Partners Management Co acquired a new position in shares of Corium International during the second quarter worth about $152,000. Opaleye Management Inc. increased its position in shares of Corium International by 1.4% in the first quarter. Opaleye Management Inc. now owns 360,000 shares of the biopharmaceutical company’s stock worth $1,390,000 after buying an additional 5,000 shares in the last quarter. Finally, RTW Investments LLC increased its position in shares of Corium International by 3.0% in the second quarter. RTW Investments LLC now owns 852,961 shares of the biopharmaceutical company’s stock worth $2,960,000 after buying an additional 24,629 shares in the last quarter. 88.35% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece was first published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright law. The original version of this piece can be read at https://www.thecerbatgem.com/2016/11/24/corium-international-inc-cori-pt-set-at-16-00-by-leerink-swann.html.

About Corium International

Corium International, Inc is a biopharmaceutical company. The Company is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. Its development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules.

5 Day Chart for NASDAQ:CORI

Receive News & Stock Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related stocks with our FREE daily email newsletter.